Table 1: Comparing the advantages of disadvantages of using docetaxel, abiraterone, enzalutamide, and apalutamide in metastatic hormone-sensitive prostate cancer
|
|
Close |
|
Table 1: Comparing the advantages of disadvantages of using docetaxel, abiraterone, enzalutamide, and apalutamide in metastatic hormone-sensitive prostate cancer
|
|